Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Use of Zevalin to Enhance the Efficacy of Non-Myeloablative Allogeneic Transplantation in Patients With Relapsed or Refractory CD20+ Non-Hodgkins Lymphoma

Trial Profile

Use of Zevalin to Enhance the Efficacy of Non-Myeloablative Allogeneic Transplantation in Patients With Relapsed or Refractory CD20+ Non-Hodgkins Lymphoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Mar 2019

At a glance

  • Drugs Ibritumomab tiuxetan (Primary) ; Antithymocyte globulin; Ciclosporin; Ciclosporin; Mycophenolate mofetil; Mycophenolate mofetil; Rituximab
  • Indications Graft-versus-host disease; Non-Hodgkin's lymphoma
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 20 Mar 2019 Planned End Date changed from 1 Feb 2019 to 1 Jun 2020.
    • 20 Mar 2019 Planned primary completion date changed from 1 Feb 2019 to 1 Jan 2020.
    • 02 Jan 2019 Planned End Date changed from 1 Jan 2019 to 1 Feb 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top